0749 GMT - GSK's specialty medicines business continues to drive momentum and a successful reintroduction of multiple myeloma drug Blenrep to the U.S. market will be key, Shore Capital Markets analyst Sean Conroy says in a note. The British drugmaker's HIV drugs are performing in line with oncology, sustaining growth, he says. Sales of RSV vaccine jab Arexvy slumped but are expected to be weighted toward the second half of the year, supported by expanded recommendations, the analyst says. Shares are up 1.4% at 1,453.50 pence. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 30, 2025 03:49 ET (07:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.